Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Phase 2 Dose Ranging in Psoriasis
NCT01071252Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in plaque psoriasis (5 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at 13 weeks. Started Mar 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01071252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071252.